Viloxazine

Publication Details

Estimated reading time: 1 minute

CASRN: 46817-91-8

image 388382610 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

The amounts of viloxazine and its active metabolite in milk appear to be low. If viloxazine is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more infant outcome data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. The manufacturer reports a study in 15 lactating women took viloxazine 600 mg daily for 3 days. The mean total amounts of viloxazine and its metabolite, 5-HVLX-gluc excreted in 24 hours at steady-state were 0.511 mg and 0.0357 mg, or 0.085 mg/kg and 0.00595 mg/kg, respectively in a 6 kg infant. These amounts were estimated to result in a relative infant dose of 1% and 0.07%, respectively.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(ADHD) Amphetamine, Dextroamphetamine, Lisdexamfetamine, Methylphenidate

Substance Identification

Substance Name

Viloxazine

CAS Registry Number

46817-91-8

Drug Class

Breast Feeding

Lactation

Milk, Human

Adrenergic Uptake Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.